Key points are not available for this paper at this time.
Treatment of pediatric GHD with lonapegsomatropin in the enliGHten trial provided robust growth outcomes and maintained a safety profile comparable to that of daily GH in a population with a broad range of pubertal statuses.
Maniatis et al. (Thu,) studied this question.